Boils Clinical Trial - Open & Comparative Study to Measure Tolerability &

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03275870` - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa	Phase 1/Phase 2
	Completed	`NCT00746109` - Study of Wound Packing After Superficial Skin Abscess Drainage	Phase 4

See also

Status

Clinical Trial

Phase

Completed

NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

Phase 1/Phase 2

Completed

NCT00746109 - Study of Wound Packing After Superficial Skin Abscess Drainage

Phase 4

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT01032499
Study type	Interventional
Source	Laboratorios Goulart S.A.
Contact	Carlos Machado
Phone	+55 11 4993-5400
Email	dermatologia@fmabc.br
Status	Not yet recruiting
Phase	Phase 3
Start date	May 2010
Completion date	October 2010

Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir — E01GOU-INH0109

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms